Neoadjuvant Chemoradiotherapy for Advanced Rectal Cancer

1Professor of general surgery and surgical oncology, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran & Petroleum & Environmental Pollutant Cancer Research Center

2Assistant Professor of radiotherapy and oncology, Department of Radiotherapy and Oncology, Golestan Hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

3Professor of general surgery, Department of Surgery, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

4General Surgeon, Department of Surgery, Razi Hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

Jundishapur Journal of Oncology:Vol. 2, issue 1; 25-27

Published online:May 26, 2016

Article type:Research Article

How to Cite:Abdolhassan TalaiezadehHodjatollah ShahbazianMohammad Hosein Sarmast ShushtariSeyyed Mohammad HoseiniSeyyed Saheb HoseininejadNeoadjuvant Chemoradiotherapy for Advanced Rectal Cancer.2(1):e148184.https://doi.org/10.22118/jjo.2016.49333.

Abstract

Background: There is some evidence that neoadjuvant chemoradiation for stages II and III rectal tumors associated with significant greater rate of complete pathologic response and sphincter preservation. The aim of this study was to determine the outcome of neoadjuvant chemoradiation in patients with advanced rectal cancer.
Materials and Methods: In this retrospective investigation, the medical records of all patients with stage II or III that underwent neoadjuvant chemoradiation (during 2005-2010) were studied. Radiotherapy was delivered by 4500-5000cGy/25-28f for 25-28 sessions, and oral 5-FU and weekly injected Eloxatin were administered. Then, all patients underwent surgery by one expert oncologist surgeon. Data include demographic data, the kind of operation, the rate of pathologic complete response and clear surgical margins and sphincter preservation were collected. Data were analyzed with SPSS software version 14.
Results: Among70 patients, the mean age was 46±13 years and 71.5% of them were male.Ten percent had the pathologic complete response, 60% had clear surgical margins. Sphincter preservation rate in cases which the distance of the tumor from anal verge was five cm or more and in cases which it was less than five cm were 51.4% and 5.6%, respectively.
Conclusion: Our results indicated that neoadjuvant chemoradiation recommended for patients with the stages II and III rectal cancers. The advantages of this modality are relatively higher chance of complete response and anal sphincter saving procedure.

Keywords

Neoadjuvant chemoradiation

rectal cancer

sphincter saving procedure

TME

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Abdolhassan Talaiezadeh:[PubMed][Scholar]
Hodjatollah Shahbazian:[PubMed][Scholar]
Mohammad Hosein Sarmast Shushtari:[PubMed][Scholar]
Seyyed Mohammad Hoseini:[PubMed][Scholar]
Seyyed Saheb Hoseininejad:[PubMed][Scholar]